SMMT Summit Therapeutics Inc.

NASDAQ
$14.19

Summit Therapeutics Inc. (SMMT) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is a loss of $0.40 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.9% since its last earnings release on November 4, 2026.

Summit Therapeutics Beat Consensus Estimates
Wednesday, November 4, 2026 · 4:36 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.40)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $14.19

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.